Direkt zum Inhalt
Merck

RNA editing: cytidine to uridine conversion in apolipoprotein B mRNA.

Biochimica et biophysica acta (2000-11-10)
A Chester, J Scott, S Anant, N Navaratnam
ZUSAMMENFASSUNG

RNA editing is a post-transcriptional process that changes the informational capacity within the RNA. These processes include alterations made by nucleotide deletion, insertion and base conversion. A to I and C to U conversion occurs in mammals and these editing events are catalysed by RNA binding deaminases. C to U editing of apoB mRNA was the first mammalian editing event to be identified. The minimal protein complex necessary for apoB mRNA editing has been determined and consists of APOBEC-1 and ACF. Overexpression of APOBEC-1 in transgenic animals caused liver dysplasia and APOBEC-1 has been identified in neurofibromatosis type 1 tumours, suggesting that RNA editing may be another mechanism for tumourigenesis. Several APOBEC-1-like proteins have been identified, including a family of APOBEC-1-related proteins with unknown function on chromosome 22. This review summarises the different types of RNA editing and discusses the current status of C to U apoB mRNA editing. This knowledge is very important in understanding the structure and function of these related proteins and their role in biology.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Uridin, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Uridin, ≥99%
Sigma-Aldrich
Cytidin, 99%
Sigma-Aldrich
Cytidin, BioReagent, suitable for cell culture, powder, ≥99%
Sigma-Aldrich
Uridin, BioUltra, ≥99%